

Supplementary Materials: Making 3D-Cry Toxin Mutants: Much More Than a Tool of Understanding Toxins Mechanism of Action

Susana Vilchez

Table S1. Sequence of some mutant toxins mentioned in the review. Parental toxin, mutant name and sequence, and domain evolved are indicated. Single mutants, which names are the same as the mutation introduced, are excluded.

Parental Toxin Evolved	Mutant Name and Sequence	Domain Evolved ¹	Reference
CryIA(b)	P26-3: A119T, M130I, G201D	DI*	[68]
	P48a14: E101K, E116K, R217H		
	P48c5: E116K, A187T		
	P36a65: T122I, A125V		
	P95a76: N123Y		
	P95a86: T188S		
	P98c1: T188S		
	P99c62: N4Y, N105Y		
	P107c22: N94K, N194K		
ICPC73	107c25: F184I	DII*	[70]
	114a30: Q95K		
CryIE	OSU 4205: ICPC73 toxin with a ICPA1 fragment from Domain II.	DIII	[77]
	G27: CryIE (DIDII)-CryIC (DIII)		
CryIA(b)	H04: CryIA(b) (DIDII)-CryIC (DIII)	DII (Loop 3)	[91]
	Triple mutant: S484A, R485A, G486A		
Cry1Ab	DF-1: Triple mutant N372A, A282G, L283S	DIII	[92]
	Cry1C/Ab hybrid: DI-DIV form Cry1C and DIV-DVII from Cry1Ab		
Cry1Ba	BBC13: Cry1Ba (DIDII)-CryIC (DIII)	DII	[81]
	BBC15: Cry1Ba (DIDII)-CryIC (DIII)		
Cry1Fa	FFC1: Cry1Fa (DIDII)-CryIC (DIII)	DIII	[79]
	A1: L1:R345A, Y350F, Y351F		
Cry3A	A2: L1:R345A, Y350, Y351	DII	[93]

Cry1Ia	1Ia/1Ia/1Ba hybrid: Cry1Ia (DIDII)-Cry1Ba (DIII)	DI, DII, DIII	[82]
Cry1Ba	1Ba/1Ia/1Ba hybrid: Cry1Ba (DI)-Cry1Ba (DIIDIII)	DI, DII, DIII	[82]
Cry4Ba using Loop3 from Cry4Aa	4BL3PAT: L3: ⁴⁵² VIPATYNS ⁴⁵⁹	DII	[103]
Cry19Aa using loop from Cry4Ba	19AL1L2: L1: ³⁵⁵ YQDLR ³⁵⁹ L2: deleted	DII	[104]
Cry1Ca and Cry1Fb using DIII of Cry1Ac	RK15: Cry1Ca (DIDII)-Cry1Ac (DIII) RK12: Cry1Fb (DIDII)-Cry1Ac (DIII)		[80]
Cry1Aa using loop 1 from Cry4Ba	1AaMosq L1: ³¹¹ YQDL ³¹⁴ L2: ³⁶⁵ GSSPG ³⁶⁹	DII	[105]
Cry8Ca2	M100: E642G M102: Q439P	DIII DII	[113]
Cry2A	D42: Deleted first 42 aa (α H1)	DI	[107]
Cry1Aa1	R5-51: L2: ²⁶¹ LSSPLYRRKSALPQVNNQELFVLD ³⁸⁴	DII (loop 2)	[133]
Cry3A	mCry3A: ¹⁵³ NPAAPERN ¹⁶⁰ Introduction of a Chimotripsin/capepsina site	DI (Loop α -helix 3 and 4)	[84]
Cry1Ia12syn th	Variant 1: D233N (DI), E639G (DIII) Variant 2: D233N (DI) Variant 3: I116T (DI), L266F (DI), K580R (DIII) Variant 4: M45V (N-terminus), D233N (DI)	DI, DII, DIII	[136]
mCry3A	eCry3.1Ab: (GenBank GU327680)	DIII	[83]
Cry8Ka1	Cry8Ka5: R82Q, Y260C, P321A, R508G, K538E, E594N	DI, DII, DIII	[137]
Cry2Ad	R24: Recombination at position ⁴¹⁶ NY ⁴¹⁷	Recombination on at DII	[119]

R26: Recombination at position ⁴⁴⁰ RPL ⁴⁴²			
R27: Recombination at position ⁴⁵⁵ GTPGGA ⁴⁶⁰			
Cry1Ab	L1-P2S: ²⁷⁸ CLMSSQAAC ²⁸⁶ L2-P2S: ³³⁵ CLMSSQAAC ³⁴³ L3-P2S: ⁴⁰¹ CLMSSQAAC ⁴⁰⁹ L1-P1Z: ²⁷⁸ CHLPRLPQC ²⁸⁶ L2-P1Z: ³³⁵ CHLPRLPQC ³⁴³	DII	[141]
Cry1Ac	A01s: Not available C04s: Not available C05s: Not available	Not available	[146]
Cry1Ai	Cry1Ai-h-loop2: ³⁹⁰ RPFNIGINNQ ⁴⁰⁰ Cry1Ai-h-loop2&3: ³⁹⁰ RPFNIGINNQ ⁴⁰⁰ ⁴⁵⁵ SMFRSGSSSSVSIIR ⁴⁶⁹	DII	[106]
Cry9Aa	Cry1Ac-Cry9Aa: Cry1Aa (DI)-Cry9Aa (DIIDIII) Cry1Ac-Cry9AaMod: Helix 1 removed	DI, DII, DIII	[85]
Chimeric protein Cry4Ba and Cry1Ac	Cry(4Ba-1Ac): Cry4Ba (DI-DIV)-Cry1Ac (DV-DVII)	DI-DVII	[21]
Cry1Aa13	Cry1Aa13-A8: L2: ³⁶⁷ GAREGSSSAYDYW ³⁷⁹ Cry1Aa13-A12: L2: ³⁶⁷ GARGDPDFDHTSYLDYC ³⁸⁵	DII	[140]
Cry11Aa, Cry11Ba, and Cry11Bb	Variant 8: (Gene bank MH068787) 73 aa deletion at N-terminal end (Domain I) and 13 aa substitutions at Domain II and III.	DI, DII, DIII	[118]
IP3-1: an artificial mutant derived from Cry3Aa1	IP3-2: 6 extra mutations: K152E, R158R, I340V, K384E, Q472L, F589L IP3-3: 8 extra mutations: K152E, R158R, E221S, K222S, I340V, K384E, Q472L, F589L IP3-4: 7 extra mutations: K63R, N97D, Q119H, K152E, R158E, F584L, M493V	DI, DII, DIII	[52]

IP3-5:

9 extra mutations:

K63R, N97D, Q119H, K152E, R158E, E221S,
K222S, F584L, M593V

IP3-6:

7 extra mutations:

K63E, K152E, R158E, Q232H, K496E,
K557H, S610T

IP3-7:

K63E, K152E, R158E, E221S, K222S, Q232H,
K496E, K557H, S610T

¹ DI: Domain 1; DII: Domain 2; DIII: Domain 3. Di *: Indicated the domain evolved although it was not known at the time.